A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT02407236 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

961

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative
Inflammatory Bowel Diseases

Interventions

DRUG: Placebo IV
DRUG: Placebo SC
DRUG: Ustekinumab IV
DRUG: Ustekinumab SC

Sponsor

Janssen Research & Development, LLC